来源: Pharmaceutical Technology
The marketing approval is valid across all 27 member states in the EU. Credit: YES Market Media via Shutterstock.
This approval is a significant step in combating serious infections caused by aerobic Gram-negative organisms. Based on the positive outcomes from the Phase III REVISIT and ASSEMBLE clinical trials assessing the treatment’s efficacy, safety, and tolerability, the EC adopted the latest decision.
Data from these studies indicate that Emblaveo is not only effective but also well-tolerated by patients, with a safety profile in line with aztreonam when used alone. 来源: Pharmaceutical Technology
Pfizer gets grant for treatment of cancer using engineered immune cells targeting bcma 来源: Pharmaceutical Technology
The latest marketing authorisation is valid across all 27 member states in the European Union (EU), including Iceland, Liechtenstein, and Norway.
Further submissions seeking approval for the treatment are planned for other countries.
This combination revitalises the activity of aztreonam against bacteria that produces metallo-β-lactamases (MBLs) and other β-lactamases, offering a new solution for treating multidrug-resistant Gram-negative bacteria. These bacteria include MBL-producing Enterobacterales and S. maltophilia, which is classified as a critical priority pathogen by the World Health Organization. Pfizer chief international commercial officer and executive vice-president Alexandre de Germay said: “The European Medicines Agency’s accelerated review of Emblaveo reflects the urgent need for new treatments to address the threat of antimicrobial resistance. “With this approval, Pfizer is proud to take another step forward in its commitment to developing and bringing breakthrough health solutions to patients impacted by serious infectious diseases around the world.” Last month, the EC awarded marketing approval to Pfizer’s Prevenar 20 for the active immunisation and protection of infants and children against common pneumococcal diseases.